Volume | 12,812,705 |
|
|||||
News | - | ||||||
Day High | 50.18 | Low High |
|||||
Day Low | 48.93 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Bristol Myers Squibb Co | BMY | NYSE | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
49.40 | 48.93 | 50.18 | 50.10 | 49.38 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
106,716 | 12,812,705 | $ 49.49 | $ 634,114,403 | - | 48.252 - 81.435 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:59:50 | formt | 179 | $ 50.14 | USD |
Bristol Myers Squibb (BMY) Options Flow Summary
Bristol Myers Squibb Co Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
101.94B | 2.03B | - | 46.16B | 6.33B | 3.11 | 16.11 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Bristol Myers Squibb News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BMY Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 49.75 | 50.18 | 48.252 | 49.10 | 12,765,174 | 0.39 | 0.78% |
1 Month | 51.36 | 53.55 | 48.252 | 50.40 | 14,320,961 | -1.22 | -2.38% |
3 Months | 60.16 | 61.425 | 48.252 | 54.37 | 13,124,681 | -10.02 | -16.66% |
6 Months | 64.46 | 66.46 | 48.252 | 58.19 | 11,259,009 | -14.32 | -22.22% |
1 Year | 80.48 | 81.435 | 48.252 | 63.40 | 9,769,625 | -30.34 | -37.7% |
3 Years | 63.15 | 81.435 | 48.252 | 66.04 | 11,011,713 | -13.01 | -20.6% |
5 Years | 53.58 | 81.435 | 41.19 | 60.71 | 12,404,286 | -3.44 | -6.42% |
Bristol Myers Squibb Description
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power. |